External validation reveals distinct plasma proteomic signatures across biopsy-proven primary glomerular diseases
Profiling 5,416 plasma proteins in Korean cohorts, the study found distinct signatures across four biopsy-proven primary glomerular diseases. An elastic-net model using 93 proteins differentiated disease subtypes and controls in discovery and external validation cohorts. It achieved AUCs above 0.8 for minimal change disease, membranous nephropathy and IgA nephropathy; the model correctly classified 14 of 15 minimal-change cases and 20 of 32 IgA-nephropathy cases, but only 3 of 14 focal-segmental glomerulosclerosis cases. Functional analysis highlighted hemostasis-related proteins in minimal change disease.
Technology: Elastic-net-regularized logistic regression using plasma proteomic features
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Profiling 5,416 plasma proteins in Korean cohorts, the study found distinct signatures across four biopsy-proven primary glomerular diseases.
- Still unknown: The discovery cohort contained 147 participants and the external validation cohort 85; subtype-level validation samples were small. Classification was strong for minimal change disease, membranous nephropathy and IgA nephropathy but poor for focal segmental glomerulosclerosis (3/14 correctly classified). The findings support cohort-level proteomic differentiation and do not establish a clinically deployable noninvasive replacement for kidney biopsy or causal roles for the selected proteins.
- AI role: The model used elastic-net regularization to select and combine a 93-protein plasma signature for classifying biopsy-proven primary glomerular disease subtypes and controls. The model was evaluated in an independent external validation cohort. Functional analysis of key proteins was used to characterize subtype-associated pathways, including hemostasis in minimal change disease.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41779447/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.